The Lipitor Warning for GLP-1 Drugmakers
Pfizer’s Lipitor experience shows the structural risks that today’s GLP-1 innovators may soon face
False
Advertisement
Related Content
Development & Clinical
Small Molecules
Business & Trends
The Staying Power of Small Molecules
October 8, 2026
4 min read
We asked the 2026 Power List whether newer modalities have eclipsed small molecules – and where the traditional mainstay still wins
Development & Clinical
Biopharma
Interviews
Musings from The Power List: Andres Sirulnik
October 5, 2026
4 min read
Regeneron's L. Andres Sirulnik explains why modernizing clinical trials is as important as developing new medicines
Development & Clinical
Cell & Gene
Interviews
Musings from The Power List: Fabian Gerlinghaus
October 1, 2026
3 min read
Cellares Co-Founder and CEO discusses why the future of cell therapy depends on rethinking how therapies are made
Cell & Gene
In vivo CAR‑T – Reimagining Immune Engineering with Direct Cell Reprogramming
September 30, 2026
10 min read
How direct T-cell reprogramming could simplify CAR-T manufacturing, expand patient access, and extend cellular immunotherapy to new indications